Thermo Fisher's fair value anchor jumped to $750.92 from $686.64 after the Q3 beat and higher guidance. The Street is mostly hiking targets on Patheon, AI exposure and margin expansion, while DZ Bank

What happened: The fair value estimate for Thermo Fisher Scientific ($TMO) rose after a Q3 beat and higher guidance, with several firms raising price targets. Key numbers: Fair value moved from US$686.64 to US$750.92. Revenue growth adjusted from 5.75% to 5.82%. Net profit margin revised from 18.15% to 19.04%. Future P/E updated from 31.0x to 31.6x. Why it matters: Analysts point to Q3 performance, Patheon and AI exposure, and end market trends as supportive of growth ambitions, while RBC flags structural risk around the 7% long term organic growth aspiration. Market: -1.7% today ($697.00), +17.9% YTD, 0.9x vol — as of 22:46 UTC

The fair value estimate for Thermo Fisher Scientific ($TMO) rose after a Q3 beat and higher guidance, with several firms raising price targets.

Analysts point to Q3 performance, Patheon and AI exposure, and end market trends as supportive of growth ambitions, while RBC flags structural risk around the 7% long term organic growth aspiration. Market: -1.7% today ($697.00), +17.9% YTD, 0.9x vol — as of 22:46 UTC